Noxopharm Limited (ASX:NOX) has disclosed a change in the director's interest of Fred Bart, following the issue of 496,141 fully paid ordinary shares in lieu of directors' fees on 20 November 2026, after shareholder approval was granted on 17 November 2026.

Key Points

  • 496,141 fully paid ordinary shares were issued to Fred Bart on 20 November 2026 in lieu of directors' fees
  • Shares were issued at $0.0907 per fully paid ordinary share as non-cash consideration
  • Shareholder approval for the share issue was obtained on 17 November 2026
  • Fred Bart's direct holding increased from 7,507,813 to 8,003,954 ordinary fully paid shares
  • The interests were not traded during a closed period

Share Issue Details and Consideration

According to the filing, the 496,141 fully paid ordinary shares were issued to Fred Bart on 20 November 2026 as direct holdings. The shares were issued for non-cash consideration at a price of $0.0907 per fully paid ordinary share. The nature of the transaction was recorded as shares issued in lieu of directors' fees. No securities were disposed of in connection with this change, and no changes were recorded to Bart's unlisted options or convertible notes holdings.

Director's Securities Holdings After Change

Following the change, Fred Bart's securities holdings in Noxopharm comprise three classes. His direct holding of fully paid ordinary shares stands at 8,003,954, up from the prior holding of 7,507,813. Through the indirect holding vehicle 4F Investments Pty Limited, Bart retains 250,000 unlisted options exercisable at $0.1488, expiring 10 September 2027, unchanged from before. Also held indirectly through 4F Investments Pty Limited are 1,250,000 convertible notes, which also remain unchanged.

Shareholder Approval and Closed Period Status

The filing states that shareholder approval for the share issue in lieu of directors' fees was obtained on 17 November 2026, with the shares subsequently issued on 20 November 2026. The previous director's interest notice for Fred Bart was dated 12 December 2025. The filing confirms the interests in securities detailed were not traded during a closed period where prior written clearance was required. No changes to director's interests in contracts were disclosed in the filing.